Protein_Domain

Part:BBa_K3672002

Designed by: Mingyao Wang   Group: iGEM20_SCU-WestChina   (2020-10-26)
Revision as of 06:39, 26 October 2020 by 305344 (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


CILY，collagen I targeting probe

CILY possessed inhibitory activity on type I collagen-induced platelet aggregation and the release of ATP. As recorded, it has a higher binding affinity (Kd:10nM) to collagen type I than the modified version, SILY, but the modification allowed dermatan sulfate to be conjugated to the terminus of the peptide.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


References


  1. Chiang, T. M. (2000). A Synthetic Nonapeptide Derived from the Sequence of a Platelet Type I Collagen Receptor Inhibits Type I Collagen-Mediated Platelet Aggregation. The American Journal of the Medical Sciences, 320(6), 362–367. doi:10.1097/00000441-200012000-00002
  2. Wahyudi H, Reynolds AA, Li Y, Owen SC, Yu SM. Targeting collagen for diagnostic imaging and therapeutic delivery. J Control Release. 2016;240:323-331. doi:10.1016/j.jconrel.2016.01.007

[edit]
Categories
Parameters
None